In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L

BMC Structural Biology

Volumn 14, Issue 1, 2014, Pages

  Morishita, Masayo ^a   Mevius, Damiaan ^a   Di Luccio, Eric ^a  

^a Kyungpook National University   (South Korea)

Author keywords

Epigenetic therapy of cancer; Histone lysine methyltransferase; HMTase inhibitors; NSD1; NSD2 MMSET WHSC1; NSD3 WHSC1L

Indexed keywords

HISTONE H3; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE; PROTEIN H3K27; PROTEIN H3K36; PROTEIN H3K4; PROTEIN H3K79; PROTEIN H3K9; PROTEIN H4K20; PROTEIN MMSET; PROTEIN NSD1; PROTEIN NSD2; PROTEIN NSD3; PROTEIN WHSC1; PROTEIN WHSC1L; UNCLASSIFIED DRUG; HISTONE; LYSINE; NSD1 PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; WHSC1 PROTEIN, HUMAN; WHSC1L1 PROTEIN, HUMAN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVE SITE; HISTONE METHYLATION; HUMAN; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN FAMILY; PROTEIN MODIFICATION; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; METHYLATION; PROCEDURES; PROTEIN SECONDARY STRUCTURE;

CATALYTIC DOMAIN; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; IN VITRO TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSINE; METHYLATION; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN STRUCTURE, SECONDARY; REPRESSOR PROTEINS;

EID: 84964314349     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/s12900-014-0025-x     Document Type: Article

References (57)

1. Krogan NJ, Kim M, Tong A, Golshani A, Cagney G, Canadien V, Richards DP, Beattie BK, Emili A, Boone C, Shilatifard A, Buratowski S, Green Blatt J: Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol 2003, 23(12):4207-4218.
2. Hudlebusch HR, Santoni-Rugiu E, Simon R, Ralfkiaer E, Rossing HH, Johansen JV, Jorgensen M, Sauter G, Helin K: The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res 2011, 17(9):2919-2933.
3. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R, Alaminos M, Cheung NK, Rahman N, Esteller M: Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A 2009, 106(51):21830-21835.
4. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung HJ, Gao AC, Zou JX, Chen HW: Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012, 32(15):3121-3131.
5. Kim JY, Kee HJ, Choe NW, Kim SM, Eom GH, Baek HJ, Kook H, Seo SB: Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol 2008, 28(6):2023-2034.
6. Kim SM, Kee HJ, Eom GH, Choe NW, Kim JY, Kim YS, Kim SK, Kook H, Seo SB: Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity. Biochem Biophys Res Commun 2006, 345(1):318-323.
7. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000, 403(6765):41-45.
8. Zhang X, Wen H, Shi X: Lysine methylation: beyond histones. Acta Biochim Biophys Sin (Shanghai) 2012, 44(1):14-27.
9. Morishita M, di Luccio E: Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1. Biochem Biophys Res Commun 2011, 412(2):214-219.
10. Morishita M, di Luccio E: Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta 2011, 1816(2):158-163.
11. Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC, Morgan GJ: MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J 2013, 3:e114.
12. Kang D, Cho HS, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Hayami S, Tsunoda T, Field HI, Matsuda K, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R: The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer 2013, 52(2):126-139.
13. Wagner EJ, Carpenter PB: Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 2012, 13(2):115-126.
14. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will C, Neri A, Kelleher NL, Yu J, Licht JD: The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 2012, 32(23):2882-2890.
15. Varier RA, Timmers HT: Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 2011, 1815(1):75-89.
16. Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S, Takawa M, Iwai Y, Daigo Y, Tsuchiya E, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, Nakamura Y, Hamamoto R: Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 2011, 13(10):887-898.
17. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, Lou Z: MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011, 470(7332):124-128.
18. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD: The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011, 117(1):211-220.
19. Kurdistani SK: Histone modifications in cancer biology and prognosis. Prog Drug Res 2011, 67:91-106.
20. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcia BA, Li W, Gozani O: NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011, 44(4):609-620.
21. Schneider R, Bannister AJ, Kouzarides T: Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002, 27(8):396-402.
22. Zhao F, Chen Y, Li R, Zeng R, Wen L, Liu Y, Zhang C: Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol 2010, 646(1-3):1-11.
23. Lucio-Eterovic AK, Singh MM, Gardner JE, Veerappan CS, Rice JC, Carpenter PB: Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proc Natl Acad Sci U S A 2010, 107(39):16952-16957.
24. Wang GG, Cai L, Pasillas MP, Kamps MP: NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007, 9(7):804-812.
25. Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T, Negrini M, Martelli MF, Mecucci C: NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002, 99(10):3857-3860.
26. Marango J, Shimoyama M, Nishio H, Meyer JA, Min D-J, Sirulnik A, Martinez-Martinez Y, Chesi M, Bergsagel PL, Zhou M-M, Waxman S, Leibovitch BA, Walsh MJ, Licht JD: The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008, 111(6):3145-3154.
27. Rayasam GV, Wendling O, Angrand P-O, Mark M, Niederreither K, Song L, Lerouge T, Hager GL, Chambon P, Losson R: NSD1 is essential for early post-implantation development and has a catalytically active SET domain. Embo J 2003, 22(12):3153-3163.
28. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O-Gara BP, Bloomfield CD, Mr?zek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ: Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 2009, 106(31):12950-12955.
29. Lucio-Eterovic A: An open and shut case for the role of NSD proteins as oncogenes. Transcription 2011, 2(4):158-161.
30. Strahl BD, Grant PA, Briggs SD, Sun Z-W, Bone JR, Caldwell JA, Mollah S, Cook RG, Shabanowitz J, Hunt DF, Allis CD: Set2 Is a Nucleosomal Histone H3-Selective Methyltransferase That Mediates Transcriptional Repression. Mol Cell Biol 2002, 22(5):1298-1306.
31. Kang HB, Choi Y, Lee JM, Choi KC, Kim HC, Yoo JY, Lee YH, Yoon HG: The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription. FEBS Lett 2009, 583(12):1880-1886.
32. Kassambara A, Klein B, Moreaux J: MMSET is overexpressed in cancers: Link with tumor aggressiveness. Biochem Biophys Res Commun 2009, 379(4):840-845.
33. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, Morgan GJ: MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 2009, 94(1):78-86.
34. Li J, Yin C, Okamoto H, Mushlin H, Balgley BM, Lee CS, Yuan K, Ikejiri B, Glasker S, Vortmeyer AO, Oldfield EH, Weil RJ, Zhuang Z: Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro Oncol 2008, 10(1):45-51.
35. Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P: NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001, 74(1):79-88.
36. Li Y, Trojer P, Xu CF, Cheung P, Kuo A, Drury WJ 3rd, Qiao Q, Neubert TA, Xu RM, Gozani O, Reinberg D: The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 2009, 284(49):34283-34295.
37. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ 3rd, Voigt P, Martin SR, Taylor WR, De Marco V, Pirrotta V, Reinberg D, Gamblin SJ: Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009, 461(7265):762-767.
38. Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ, Kaneda Y: A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009, 460(7252):287-291.
39. Zhou Z, Thomsen R, Kahns S, Nielsen AL: The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells. Biochem Biophys Res Commun 2010, 398(3):565-570.
40. Fang R, Barbera AJ, Xu Y, Rutenberg M, Leonor T, Bi Q, Lan F, Mei P, Yuan GC, Lian C, Peng J, Cheng D, Sui G, Kaiser UB, Shi Y, Shi YG: Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell 2010, 39(2):222-233.
41. Taketani T, Taki T, Nakamura H, Taniwaki M, Masuda J, Hayashi Y: NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 2009, 190(2):108-112.
42. Lu T, Jackson MW, Wang B, Yang M, Chance MR, Miyagi M, Gudkov AV, Stark GR: Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 2010, 107(1):46-51.
43. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM: Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. Mol Cell 2012, 49(1):80-93.
44. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL: The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998, 92(9):3025-3034.
45. Xie Z, Chng WJ: MMSET: role and therapeutic opportunities in multiple myeloma. BioMed research international 2014, 2014:636514.
46. He C, Li F, Zhang J, Wu J, Shi Y: The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. J Biol Chem 2013, 288(7):4692-4703.
47. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K: Scalable molecular dynamics with NAMD. J Comput Chem 2005, 26(16):1781-1802.
48. Wallace AC, Laskowski RA, Thornton JM: LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995, 8(2):127-134.
49. Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60(Pt 12 Pt 1):2126-2132.
50. Wang Y, Reddy B, Thompson J, Wang H, Noma K, Yates JR 3rd, Jia S: Regulation of Set9-mediated H4K20 methylation by a PWWP domain protein. Mol Cell 2009, 33(4):428-437.
51. Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, Xu RM: The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem 2011, 286(10):8361-8368.
52. Wu H, Min J, Lunin VV, Antoshenko T, Dombrovski L, Zeng H, Allali-Hassani A, Campagna-Slater V, Vedadi M, Arrowsmith CH, Plotnikov AN, Schapira M: Structural biology of human H3K9 methyltransferases. PLoS One 2010, 5(1):e8570.
53. Southall SM, Wong PS, Odho Z, Roe SM, Wilson JR: Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell 2009, 33(2):181-191.
54. Morris SA, Shibata Y, Noma K, Tsukamoto Y, Warren E, Temple B, Grewal SIS, Strahl BD: Histone H3K36 methylation is associated with transcription elongation in Schizosaccharomyces pombe. Eukaryotic Cell 2005, 4(8):1446-1454.
55. Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, Figeys D: The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics 2008, 7(3):560-572.
56. Wang D, Zhou J, Liu X, Lu D, Shen C, Du Y, Wei FZ, Song B, Lu X, Yu Y, Wang L, Zhao Y, Wang H, Yang Y, Akiyama Y, Zhang H, Zhu WG: Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability. Proc Natl Acad Sci U S A 2013, 110(14):5516-5521.
57. Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, Komatsu Y, Shinkai Y, Cheng XD, Jeltsch A: Protein lysine methyltransferase G9a acts on non-histone targets. Nat Chem Biol 2008, 4(6):344-346.